PER 3.38% 7.7¢ percheron therapeutics limited

Ann: Dosing commenced in the ATL1102 toxicology study, page-7

  1. 2,956 Posts.
    lightbulb Created with Sketch. 116
    Whilst ANP maintains the current management structure (CEO) and no funding pathways this one is going anywhere.

    Current news coming out of ANP has been fantastic, however these 2 aspects imo has the market and big investors sitting back watching and waiting.

 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.